Genmab A/S (GMAB)
Price trend score is near the top of its range, with business numbers score (revenue, margins, returns) is near the top of its range.
GMAB scores higher than 95% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Genmab A/S (GMAB) scores 68 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.75× 30-day average
- 52-week range
- 23.62 – 40.17
- Market cap
- $134.12B
- Earnings date
- —
- Volume
- 2,333,446
- Avg. volume (30d)
- 3,102,704
- Open
- 36.55
- Previous close
- 36.05
- Day's range (regular session)
- 36.33 – 37.15
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.67
- P/E (TTM)
- 28.22
- EPS (TTM)
- 12.69
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about GMAB right now
Genmab A/S (GMAB) currently scores 68/100 on the Market Census six-factor composite, at the Above average score level. GMAB is +2.83% on the day and +6.53% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for GMAB leans good, with some weak spots. GMAB's strongest factor is price trend at 97/100 — a very strong read on which way the price has been going. The weakest factor is market mood at 50/100 — middling backdrop. A weak market mood drags every name in the cohort; if GMAB is still scoring well on the composite despite this, the company-specific factors must be doing heavy lifting.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See GMAB in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent GMAB news
Latest headlines that name Genmab, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board MembersYahoo
- Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaGlobeNewswire Inc.
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian CancerGlobeNewswire Inc.
- Major Shareholder AnnouncementYahoo
- Genmab Announces That Darwin Global Management Now Controls 3,188,361 Shares, 5.11% Of Voting RightsBenzinga
We hide 7 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to GMAB’s 68, all within 1 point.
Sorted by closeness to GMAB’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.